Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
Read More
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin
Published: June 12, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese.
Read More
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management.
Read More
NVO Stock Gains After Parvus Asset Management Builds Stake
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Read More
Novo Nordisk: The Time To Buy Has Come
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investors. Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market, despite revised guidance due to compounded drug impacts. NVO actively combats compounded GLP-1s via legal routes, new patient access programs like $499 Wegovy, and key formulary wins such as CVS exclusivity.
Read More
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Read More
Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds
Published: May 27, 2025 by: Proactive Investors
Sentiment: Neutral
A fresh physician poll has revived debate over the shifting balance of power in the weight-loss drug market. According to Deutsche Bank, the snapshot shows a marginal swing in favour of Eli Lilly and Co's (NYSE:LLY) Zepbound over Novo Nordisk's (NYSE:NVO) Wegovy.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Is Novo Nordisk Immune To President Trump's Drug Price Plans
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products and the successes achieved in developing its clinical-stage projects. So, the semaglutide franchise's total sales reached DKK 50 billion in the first quarter of 2025, an increase of 18.7% year-on-year.
Read More
Final Trade: AAPL, NVO, TLT, X
Published: May 23, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Read More
Mizuho's Jared Holz talks what is next for Novo Nordisk
Published: May 23, 2025 by: CNBC Television
Sentiment: Negative
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
3 Overlooked Dividend Growers With 10%+ Annual Dividend Increases
Published: May 22, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks can significantly amplify the compounding of your portfolio.
Read More
Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers
Published: May 22, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.
Read More
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide" Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredients PLAINSBORO, N.J. , May 22, 2025 /PRNewswire/ -- …
Read More
Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO
Published: May 22, 2025 by: Reuters
Sentiment: Neutral
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)
Published: May 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Novo Nordisk Woes Weigh on Denmark's Economy. Here's How.
Published: May 20, 2025 by: Barrons
Sentiment: Negative
Denmark's economy contracted 0.5% in the first quarter of 2025, largely due to the pharmaceutical industry.
Read More
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Published: May 19, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
Read More
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
Read More
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S' share price decline is driven by negative sentiment despite strong sales growth, profitability, and efficiency metrics. Competition from Eli Lilly and supply issues have pressured market share, but Novo Nordisk remains highly profitable with a robust financial position. Recent CEO departure and pipeline setbacks have fueled pessimism, yet ongoing investments and U.S. expansion support long-term prospects.
Read More
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.
Read More
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Published: May 16, 2025 by: New York Post
Sentiment: Negative
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.
Read More
Novo Nordisk CEO to step down, citing market challenges
Published: May 16, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk.
Read More
SPX 6000 Close? Plus, NVO CEO Out, CAVA Dip and Buffett's STZ Position
Published: May 16, 2025 by: Schwab Network
Sentiment: Neutral
Kevin Green joins Morning Trade Live as markets open mixed to begin Friday's trading. For the intraday S&P 500 (SPX) ranges KG is watching, he points to 5960-5970 for upward resistance.
Read More
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Read More
Novo Nordisk Stock Suffers After C-Suite Shakeup
Published: May 16, 2025 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) is down 3.9% to trade at $63.60 this morning, after a C-suite shakeup.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406